EGFR exon 20 mutant inhibitor, oral once-daily

Breakthrough Therapy for ex20+ NSCLC (Ph. I)

from cellular screening + SBDD

Cancer Discovery, Feb. 25, 2021

ARIAD/Takeda, Cambridge, MA

Mobocertinib-(TAK-788)

4. The ARIAD/Takeda EGFR exon 20 insertion mutant (EGFRex20ins) inhibitor TAK-788 is a Breakthrough Therapy for patients with advanced non-small cell lung cancer (NSCLC) whose tumors harbor EGFR exon…


get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: